Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Klebsiella pneumoniae cell surface structures are a heterogeneous group of macromolecules, primarily comprising the capsular polysaccharide (CPS), lipopolysaccharide (LPS), fimbriae (pili), and outer membrane proteins (OMPs) (Paczosa & Mecsas, 2016, Microbiology and Molecular Biology Reviews). These components are fundamental to the bacterium's pathogenicity, acting as a protective barrier against host immune defenses such as phagocytosis and the complement system, while also facilitating colonization through adhesion to host tissues (Li et al., 2014, Future Microbiology). The CPS, or K antigen, is particularly critical for virulence, with certain serotypes like K1 and K2 being strongly associated with hypervirulent invasive infections (Shon et al., 2013, Lancet Infectious Diseases). In therapeutic contexts, these surface components serve as primary targets for both traditional and novel interventions. Polymyxin antibiotics, such as Colistin, exert their effect by binding to the lipid A portion of the LPS, leading to membrane disruption and cell death (Trimble et al., 2016, Cold Spring Harbor Perspectives in Medicine). Modern research is increasingly focused on developing monoclonal antibodies and vaccines that target specific K or O antigens to enhance immune clearance, as well as utilizing bacteriophages that recognize these surface structures as entry receptors (Diago-Navarro et al., 2017, mBio; Townsend et al., 2021, Frontiers in Cellular and Infection Microbiology).
Disruption of the bacterial outer membrane through binding to lipopolysaccharide (LPS); Opsonization and enhancement of phagocytosis via antibody binding to capsular polysaccharides; Inhibition of bacterial adhesion to host tissues by targeting fimbriae.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Klebsiella pneumoniae cell surface structures.